Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.

Autor: Ferrari MD; Leiden University Medical Centre, Leiden, The Netherlands., Zuurbier KWM; Teva Netherlands B.V., Haarlem, The Netherlands., Barash S; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA., Ning X; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA., Cohen JM; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Headache [Headache] 2022 Apr; Vol. 62 (4), pp. 530-533. Date of Electronic Publication: 2022 Apr 06.
DOI: 10.1111/head.14294
Databáze: MEDLINE
Externí odkaz: